{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:04:28Z","timestamp":1779141868963,"version":"3.51.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012288","name":"Breast Cancer Coalition of Rochester","doi-asserted-by":"publisher","award":["2015"],"award-info":[{"award-number":["2015"]}],"id":[{"id":"10.13039\/100012288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004856","name":"New York State Department of Health","doi-asserted-by":"publisher","award":["C34928GG"],"award-info":[{"award-number":["C34928GG"]}],"id":[{"id":"10.13039\/100004856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG049994"],"award-info":[{"award-number":["R01AG049994"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The most challenging issue for breast cancer (BC) patients is metastasis to other organs because current therapies do not prevent or eliminate metastatic BC. Here, we show that SM-164, a small molecule inhibitor, which degrades inhibitor of apoptosis proteins (IAPs), eliminated early-stage metastases and reduced progression of advanced BC metastasis from MDA-MB-231 BC cells in bones and lungs of nude mice. Mechanistically, SM-164-induced BC cell death is TNF\u03b1-dependent, with TNF\u03b1 produced by IL-4-polarized macrophages triggering MDA-MB-231 cell apoptosis in combination with SM-164. SM-164 also inhibited expression of RANKL, which mediates interactions between metastatic BC and host microenvironment cells and induces osteoclast-mediated osteolysis. SM-164 did not kill adriamycin-resistant BC cells, while adriamycin inhibited SM-164-resistant BC cell growth, similar to parental cells. We conclude that SM-164 is a promising therapeutic agent for early stage bone and lung metastasis from triple-negative breast cancer that should be given prior to conventional chemotherapy.<\/jats:p>","DOI":"10.1038\/s41598-020-64018-z","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T10:26:38Z","timestamp":1587723998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The IAP Antagonist SM-164 Eliminates Triple-Negative Breast Cancer Metastasis to Bone and Lung in Mice"],"prefix":"10.1038","volume":"10","author":[{"given":"Wei","family":"Lei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1279-9000","authenticated-orcid":false,"given":"Jinbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissa","family":"Huston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan F.","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4664-3648","authenticated-orcid":false,"given":"Zhenqiang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"key":"64018_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J Clin 69, 7\u201334, https:\/\/doi.org\/10.3322\/caac.21551 (2019).","journal-title":"CA Cancer J Clin"},{"key":"64018_CR2","doi-asserted-by":"publisher","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative, G. Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst Rev, CD000487, https:\/\/doi.org\/10.1002\/14651858.CD000487 (2002).","DOI":"10.1002\/14651858.CD000487"},{"key":"64018_CR3","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","volume":"366","author":"M Clarke","year":"2005","unstructured":"Clarke, M. et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366, 2087\u20132106, https:\/\/doi.org\/10.1016\/S0140-6736(05)67887-7 (2005).","journal-title":"Lancet"},{"key":"64018_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.molonc.2016.09.009","volume":"11","author":"RR Gomis","year":"2017","unstructured":"Gomis, R. R. & Gawrzak, S. Tumor cell dormancy. Mol Oncol 11, 62\u201378, https:\/\/doi.org\/10.1016\/j.molonc.2016.09.009 (2017).","journal-title":"Mol Oncol"},{"key":"64018_CR5","doi-asserted-by":"publisher","first-page":"340ra373","DOI":"10.1126\/scitranslmed.aad4059","volume":"8","author":"TT Price","year":"2016","unstructured":"Price, T. T. et al. Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. Sci Transl Med 8, 340ra373, https:\/\/doi.org\/10.1126\/scitranslmed.aad4059 (2016).","journal-title":"Sci Transl Med"},{"key":"64018_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3322\/caac.21217","volume":"64","author":"SP Leong","year":"2014","unstructured":"Leong, S. P. & Tseng, W. W. Micrometastatic cancer cells in lymph nodes, bone marrow, and blood: Clinical significance and biologic implications. CA Cancer J Clin 64, 195\u2013206, https:\/\/doi.org\/10.3322\/caac.21217 (2014).","journal-title":"CA Cancer J Clin"},{"key":"64018_CR7","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/jbmr.5650100815","volume":"10","author":"LK McCauley","year":"1995","unstructured":"McCauley, L. K. et al. Effects of differentiation and transforming growth factor beta 1 on PTH\/PTHrP receptor mRNA levels in MC3T3-E1 cells. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 10, 1243\u20131255, https:\/\/doi.org\/10.1002\/jbmr.5650100815 (1995).","journal-title":"Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research"},{"key":"64018_CR8","doi-asserted-by":"publisher","first-page":"35975","DOI":"10.1074\/jbc.M112.372458","volume":"287","author":"N Lian","year":"2012","unstructured":"Lian, N. et al. Transforming growth factor beta suppresses osteoblast differentiation via the vimentin activating transcription factor 4 (ATF4) axis. The Journal of biological chemistry 287, 35975\u201335984, https:\/\/doi.org\/10.1074\/jbc.M112.372458 (2012).","journal-title":"The Journal of biological chemistry"},{"key":"64018_CR9","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.7314\/APJCP.2014.15.4.1503","volume":"15","author":"B Erdogan","year":"2014","unstructured":"Erdogan, B. & Cicin, I. Medical treatment of breast cancer bone metastasis: from bisphosphonates to targeted drugs. Asian Pacific journal of cancer prevention: APJCP 15, 1503\u20131510 (2014).","journal-title":"Asian Pacific journal of cancer prevention: APJCP"},{"key":"64018_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14712598.2013.843667","volume":"14","author":"C Rolfo","year":"2014","unstructured":"Rolfo, C. et al. Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor. Expert opinion on biological therapy 14, 15\u201326, https:\/\/doi.org\/10.1517\/14712598.2013.843667 (2014).","journal-title":"Expert opinion on biological therapy"},{"key":"64018_CR11","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman, G. D. Mechanisms of bone metastasis. The New England journal of medicine 350, 1655\u20131664, https:\/\/doi.org\/10.1056\/NEJMra030831 (2004).","journal-title":"The New England journal of medicine"},{"key":"64018_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc3055","volume":"11","author":"KN Weilbaecher","year":"2011","unstructured":"Weilbaecher, K. N., Guise, T. A. & McCauley, L. K. Cancer to bone: a fatal attraction. Nature reviews. Cancer 11, 411\u2013425, https:\/\/doi.org\/10.1038\/nrc3055 (2011).","journal-title":"Nature reviews. Cancer"},{"key":"64018_CR13","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1210\/endo.140.10.7037","volume":"140","author":"RJ Thomas","year":"1999","unstructured":"Thomas, R. J. et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140, 4451\u20134458, https:\/\/doi.org\/10.1210\/endo.140.10.7037 (1999).","journal-title":"Endocrinology"},{"key":"64018_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/bcr1848","volume":"10","author":"LC Hofbauer","year":"2008","unstructured":"Hofbauer, L. C., Rachner, T. & Singh, S. K. Fatal attraction: why breast cancer cells home to bone. Breast cancer research: BCR 10, 101, https:\/\/doi.org\/10.1186\/bcr1848 (2008).","journal-title":"Breast cancer research: BCR"},{"key":"64018_CR15","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman, R. E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical cancer research: an official journal of the American Association for Cancer Research 12, 6243s\u20136249s, https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0931 (2006).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"64018_CR16","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/cncr.21778","volume":"106","author":"KR Hess","year":"2006","unstructured":"Hess, K. R. et al. Metastatic patterns in adenocarcinoma. Cancer 106, 1624\u20131633, https:\/\/doi.org\/10.1002\/cncr.21778 (2006).","journal-title":"Cancer"},{"key":"64018_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10677-0","volume":"10","author":"J Li","year":"2019","unstructured":"Li, J. et al. TGFbeta-induced degradation of TRAF3 in mesenchymal progenitor cells causes age-related osteoporosis. Nature communications 10, 2795, https:\/\/doi.org\/10.1038\/s41467-019-10677-0 (2019).","journal-title":"Nature communications"},{"key":"64018_CR18","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature09707","volume":"470","author":"W Tan","year":"2011","unstructured":"Tan, W. et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470, 548\u2013553, https:\/\/doi.org\/10.1038\/nature09707 (2011).","journal-title":"Nature"},{"key":"64018_CR19","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1074\/jbc.M610271200","volume":"282","author":"JQ He","year":"2007","unstructured":"He, J. Q., Saha, S. K., Kang, J. R., Zarnegar, B. & Cheng, G. Specificity of TRAF3 in its negative regulation of the noncanonical NF-kappa B pathway. The Journal of biological chemistry 282, 3688\u20133694, https:\/\/doi.org\/10.1074\/jbc.M610271200 (2007).","journal-title":"The Journal of biological chemistry"},{"key":"64018_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1158\/1078-0432.CCR-13-0227","volume":"20","author":"S Fulda","year":"2014","unstructured":"Fulda, S. Molecular pathways: targeting inhibitor of apoptosis proteins in cancer\u2013from molecular mechanism to therapeutic application. Clinical cancer research: an official journal of the American Association for Cancer Research 20, 289\u2013295, https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0227 (2014).","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"64018_CR21","doi-asserted-by":"publisher","first-page":"26243","DOI":"10.1074\/jbc.M403286200","volume":"279","author":"G Liao","year":"2004","unstructured":"Liao, G., Zhang, M., Harhaj, E. W. & Sun, S. C. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. The Journal of biological chemistry 279, 26243\u201326250, https:\/\/doi.org\/10.1074\/jbc.M403286200 (2004).","journal-title":"The Journal of biological chemistry"},{"key":"64018_CR22","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/ni.1678","volume":"9","author":"S Vallabhapurapu","year":"2008","unstructured":"Vallabhapurapu, S. et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nature immunology 9, 1364\u20131370, https:\/\/doi.org\/10.1038\/ni.1678 (2008).","journal-title":"Nature immunology"},{"key":"64018_CR23","doi-asserted-by":"publisher","first-page":"15279","DOI":"10.1021\/ja074725f","volume":"129","author":"H Sun","year":"2007","unstructured":"Sun, H. et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. Journal of the American Chemical Society 129, 15279\u201315294, https:\/\/doi.org\/10.1021\/ja074725f (2007).","journal-title":"Journal of the American Chemical Society"},{"key":"64018_CR24","doi-asserted-by":"publisher","first-page":"9384","DOI":"10.1158\/0008-5472.CAN-08-2655","volume":"68","author":"J Lu","year":"2008","unstructured":"Lu, J. et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1\/2 and XIAP. Cancer research 68, 9384\u20139393, https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2655 (2008).","journal-title":"Cancer research"},{"key":"64018_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9983","volume":"6","author":"MA Lawson","year":"2015","unstructured":"Lawson, M. A. et al. Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nature communications 6, 8983, https:\/\/doi.org\/10.1038\/ncomms9983 (2015).","journal-title":"Nature communications"},{"key":"64018_CR26","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1158\/2159-8290.CD-12-0271","volume":"3","author":"C Yang","year":"2013","unstructured":"Yang, C. et al. Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation. Cancer discovery 3, 212\u2013223, https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0271 (2013).","journal-title":"Cancer discovery"},{"key":"64018_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bone.2013.10.024","volume":"59","author":"B Jobke","year":"2014","unstructured":"Jobke, B., Milovanovic, P., Amling, M. & Busse, B. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients. Bone 59, 37\u201343, https:\/\/doi.org\/10.1016\/j.bone.2013.10.024 (2014).","journal-title":"Bone"},{"key":"64018_CR28","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","volume":"10","author":"DE Hughes","year":"1995","unstructured":"Hughes, D. E. et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 10, 1478\u20131487, https:\/\/doi.org\/10.1002\/jbmr.5650101008 (1995).","journal-title":"Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research"},{"key":"64018_CR29","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/bonekey.2016.31","volume":"5","author":"LE Wright","year":"2016","unstructured":"Wright, L. E. et al. Murine models of breast cancer bone metastasis. BoneKEy reports 5, 804, https:\/\/doi.org\/10.1038\/bonekey.2016.31 (2016).","journal-title":"BoneKEy reports"},{"key":"64018_CR30","doi-asserted-by":"publisher","first-page":"R819","DOI":"10.1186\/bcr1292","volume":"7","author":"MM Richert","year":"2005","unstructured":"Richert, M. M. et al. Metastasis of hormone-independent breast cancer to lung and bone is decreased by alpha-difluoromethylornithine treatment. Breast cancer research: BCR 7, R819\u2013827, https:\/\/doi.org\/10.1186\/bcr1292 (2005).","journal-title":"Breast cancer research: BCR"},{"key":"64018_CR31","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1158\/1535-7163.MCT-10-0864","volume":"10","author":"J Lu","year":"2011","unstructured":"Lu, J. et al. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Molecular cancer therapeutics 10, 902\u2013914, https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0864 (2011).","journal-title":"Molecular cancer therapeutics"},{"key":"64018_CR32","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1097\/JTO.0b013e318226b4a6","volume":"6","author":"W Li","year":"2011","unstructured":"Li, W. et al. BV6, an IAP antagonist, activates apoptosis and enhances radiosensitization of non-small cell lung carcinoma in vitro. J Thorac Oncol 6, 1801\u20131809, https:\/\/doi.org\/10.1097\/JTO.0b013e318226b4a6 (2011).","journal-title":"J Thorac Oncol"},{"key":"64018_CR33","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cell.2007.10.037","volume":"131","author":"JE Vince","year":"2007","unstructured":"Vince, J. E. et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131, 682\u2013693, https:\/\/doi.org\/10.1016\/j.cell.2007.10.037 (2007).","journal-title":"Cell"},{"key":"64018_CR34","doi-asserted-by":"publisher","first-page":"804","DOI":"10.4161\/cbt.20563","volume":"13","author":"MK Brunckhorst","year":"2012","unstructured":"Brunckhorst, M. K., Lerner, D., Wang, S. & Yu, Q. AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. Cancer biology & therapy 13, 804\u2013811, https:\/\/doi.org\/10.4161\/cbt.20563 (2012).","journal-title":"Cancer biology & therapy"},{"key":"64018_CR35","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","volume":"23","author":"A Mantovani","year":"2002","unstructured":"Mantovani, A., Sozzani, S., Locati, M., Allavena, P. & Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in immunology 23, 549\u2013555 (2002).","journal-title":"Trends in immunology"},{"key":"64018_CR36","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","volume":"8","author":"DM Mosser","year":"2008","unstructured":"Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nature reviews. Immunology 8, 958\u2013969, https:\/\/doi.org\/10.1038\/nri2448 (2008).","journal-title":"Nature reviews. Immunology"},{"key":"64018_CR37","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1172\/JCI59643","volume":"122","author":"A Sica","year":"2012","unstructured":"Sica, A. & Mantovani, A. Macrophage plasticity and polarization: in vivo veritas. The Journal of clinical investigation 122, 787\u2013795, https:\/\/doi.org\/10.1172\/JCI59643 (2012).","journal-title":"The Journal of clinical investigation"},{"key":"64018_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/art.11419","volume":"50","author":"P Li","year":"2004","unstructured":"Li, P. et al. Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis and rheumatism 50, 265\u2013276, https:\/\/doi.org\/10.1002\/art.11419 (2004).","journal-title":"Arthritis and rheumatism"},{"key":"64018_CR39","doi-asserted-by":"publisher","first-page":"10169","DOI":"10.1074\/jbc.M116.771816","volume":"292","author":"Z Yao","year":"2017","unstructured":"Yao, Z. et al. RANKL cytokine enhances TNF-induced osteoclastogenesis independently of TNF receptor associated factor (TRAF) 6 by degrading TRAF3 in osteoclast precursors. The Journal of biological chemistry 292, 10169\u201310179, https:\/\/doi.org\/10.1074\/jbc.M116.771816 (2017).","journal-title":"The Journal of biological chemistry"},{"key":"64018_CR40","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/onc.2016.252","volume":"36","author":"PF Yu","year":"2017","unstructured":"Yu, P. F. et al. Downregulation of CXCL12 in mesenchymal stromal cells by TGFbeta promotes breast cancer metastasis. Oncogene 36, 840\u2013849, https:\/\/doi.org\/10.1038\/onc.2016.252 (2017).","journal-title":"Oncogene"},{"key":"64018_CR41","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1124\/dmd.113.053926","volume":"41","author":"H Wong","year":"2013","unstructured":"Wong, H. et al. Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist. Drug metabolism and disposition: the biological fate of chemicals 41, 2104\u20132113, https:\/\/doi.org\/10.1124\/dmd.113.053926 (2013).","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"key":"64018_CR42","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1200\/JCO.2013.52.3993","volume":"32","author":"JR Infante","year":"2014","unstructured":"Infante, J. R. et al. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J Clin Oncol 32, 3103\u20133110, https:\/\/doi.org\/10.1200\/JCO.2013.52.3993 (2014).","journal-title":"J Clin Oncol"},{"key":"64018_CR43","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.clml.2015.02.020","volume":"15","author":"JF DiPersio","year":"2015","unstructured":"DiPersio, J. F. et al. Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia\u2013results of a phase I dose-escalation study. Clin Lymphoma Myeloma Leuk 15, 443\u2013449, https:\/\/doi.org\/10.1016\/j.clml.2015.02.020 (2015).","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"64018_CR44","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00280-015-2709-8","volume":"75","author":"HI Hurwitz","year":"2015","unstructured":"Hurwitz, H. I. et al. Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. Cancer chemotherapy and pharmacology 75, 851\u2013859, https:\/\/doi.org\/10.1007\/s00280-015-2709-8 (2015).","journal-title":"Cancer chemotherapy and pharmacology"},{"key":"64018_CR45","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/cncr.29783","volume":"122","author":"AM Noonan","year":"2016","unstructured":"Noonan, A. M. et al. Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Cancer 122, 588\u2013597, https:\/\/doi.org\/10.1002\/cncr.29783 (2016).","journal-title":"Cancer"},{"key":"64018_CR46","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1158\/1535-7163.MCT-15-0475","volume":"14","author":"RK Amaravadi","year":"2015","unstructured":"Amaravadi, R. K. et al. A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. Molecular cancer therapeutics 14, 2569\u20132575, https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0475 (2015).","journal-title":"Molecular cancer therapeutics"},{"key":"64018_CR47","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1124\/jpet.107.127704","volume":"324","author":"F Shen","year":"2008","unstructured":"Shen, F. et al. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. The Journal of pharmacology and experimental therapeutics 324, 95\u2013102, https:\/\/doi.org\/10.1124\/jpet.107.127704 (2008).","journal-title":"The Journal of pharmacology and experimental therapeutics"},{"key":"64018_CR48","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1038\/cdd.2012.59","volume":"19","author":"S McComb","year":"2012","unstructured":"McComb, S. et al. cIAP1 and cIAP2 limit macrophage necroptosis by inhibiting Rip1 and Rip3 activation. Cell death and differentiation 19, 1791\u20131801, https:\/\/doi.org\/10.1038\/cdd.2012.59 (2012).","journal-title":"Cell death and differentiation"},{"key":"64018_CR49","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1172\/JCI11066","volume":"106","author":"S Cenci","year":"2000","unstructured":"Cenci, S. et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. The Journal of clinical investigation 106, 1229\u20131237, https:\/\/doi.org\/10.1172\/JCI11066 (2000).","journal-title":"The Journal of clinical investigation"},{"key":"64018_CR50","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1158\/2326-6066.CIR-18-0428","volume":"7","author":"J Michie","year":"2019","unstructured":"Michie, J. et al. Antagonism of IAPs Enhances CAR T-cell Efficacy. Cancer Immunol Res 7, 183\u2013192, https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0428 (2019).","journal-title":"Cancer Immunol Res"},{"key":"64018_CR51","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1084\/jem.20101123","volume":"207","author":"M Dougan","year":"2010","unstructured":"Dougan, M. et al. IAP inhibitors enhance co-stimulation to promote tumor immunity. The Journal of experimental medicine 207, 2195\u20132206, https:\/\/doi.org\/10.1084\/jem.20101123 (2010).","journal-title":"The Journal of experimental medicine"},{"key":"64018_CR52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/2326-6066.CIR-17-0490","volume":"6","author":"E Clancy-Thompson","year":"2018","unstructured":"Clancy-Thompson, E. et al. IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells. Cancer Immunol Res 6, 25\u201335, https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0490 (2018).","journal-title":"Cancer Immunol Res"},{"key":"64018_CR53","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/j.1745-7254.2008.00889.x","volume":"29","author":"X Wang","year":"2008","unstructured":"Wang, X. & Lin, Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin 29, 1275\u20131288, https:\/\/doi.org\/10.1111\/j.1745-7254.2008.00889.x (2008).","journal-title":"Acta Pharmacol Sin"},{"key":"64018_CR54","first-page":"588","volume":"9","author":"RP Whitehead","year":"1990","unstructured":"Whitehead, R. P. et al. A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study. J Biol Response Mod 9, 588\u2013591 (1990).","journal-title":"J Biol Response Mod"},{"key":"64018_CR55","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/BF00257449","volume":"24","author":"H Lenk","year":"1989","unstructured":"Lenk, H., Tanneberger, S., Muller, U., Ebert, J. & Shiga, T. Phase II clinical trial of high-dose recombinant human tumor necrosis factor. Cancer chemotherapy and pharmacology 24, 391\u2013392 (1989).","journal-title":"Cancer chemotherapy and pharmacology"},{"key":"64018_CR56","doi-asserted-by":"publisher","unstructured":"Boorsma, C., Draijer, C. & Cool, R. The RANKL-OPG balance in pulmonary fibrosis. European Respiratory Journal, https:\/\/doi.org\/10.1183\/13993003 (2015).","DOI":"10.1183\/13993003"},{"key":"64018_CR57","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drup.2017.10.003","volume":"32","author":"I Genovese","year":"2017","unstructured":"Genovese, I., Ilari, A., Assaraf, Y. G., Fazi, F. & Colotti, G. Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy 32, 23\u201346, https:\/\/doi.org\/10.1016\/j.drup.2017.10.003 (2017).","journal-title":"Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"64018_CR58","first-page":"389","volume":"4","author":"E Mechetner","year":"1998","unstructured":"Mechetner, E. et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clinical cancer research: an official journal of the American Association for. Cancer Research 4, 389\u2013398 (1998).","journal-title":"Cancer Research"},{"key":"64018_CR59","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1093\/emboj\/17.8.2215","volume":"17","author":"QL Deveraux","year":"1998","unstructured":"Deveraux, Q. L. et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. The EMBO journal 17, 2215\u20132223, https:\/\/doi.org\/10.1093\/emboj\/17.8.2215 (1998).","journal-title":"The EMBO journal"},{"key":"64018_CR60","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1021\/jm300060k","volume":"55","author":"JA Flygare","year":"2012","unstructured":"Flygare, J. A. et al. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). Journal of medicinal chemistry 55, 4101\u20134113, https:\/\/doi.org\/10.1021\/jm300060k (2012).","journal-title":"Journal of medicinal chemistry"},{"key":"64018_CR61","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1172\/JCI38716","volume":"119","author":"Z Yao","year":"2009","unstructured":"Yao, Z., Xing, L. & Boyce, B. F. NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. The Journal of clinical investigation 119, 3024\u20133034, https:\/\/doi.org\/10.1172\/JCI38716 (2009).","journal-title":"The Journal of clinical investigation"},{"key":"64018_CR62","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/jbmr.2108","volume":"29","author":"Z Yao","year":"2014","unstructured":"Yao, Z. et al. NF-kappaB RelB negatively regulates osteoblast differentiation and bone formation. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 29, 866\u2013877, https:\/\/doi.org\/10.1002\/jbmr.2108 (2014).","journal-title":"Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research"},{"key":"64018_CR63","doi-asserted-by":"publisher","first-page":"18245","DOI":"10.1074\/jbc.M610701200","volume":"282","author":"T Yamashita","year":"2007","unstructured":"Yamashita, T. et al. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. The Journal of biological chemistry 282, 18245\u201318253, https:\/\/doi.org\/10.1074\/jbc.M610701200 (2007).","journal-title":"The Journal of biological chemistry"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64018-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64018-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64018-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T09:49:41Z","timestamp":1670320181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64018-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["64018"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-64018-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,24]]},"assertion":[{"value":"11 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7004"}}